Kidney drug trial halted early: what happened with VB119?
NCT ID NCT04652570
First seen Feb 14, 2026 · Last updated May 20, 2026 · Updated 12 times
Summary
This study tested an experimental drug, VB119, in 6 adults with primary membranous nephropathy, a kidney disease that causes protein leakage. The goal was to check safety and find the right dose. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Research Site
Albany, New York, 12209, United States
-
Clinical Research Site
Bethlehem, Pennsylvania, 18017, United States
-
Clinical Research Site
Dallas, Texas, 75208, United States
-
Clinical Reserach Site
Los Angeles, California, 91324, United States
Conditions
Explore the condition pages connected to this study.